Society for Immunotherapy of Cancer (SITC) shared a post on LinkedIn:
“Join leading experts as they explore emerging modalities Beyond PD-1, discussing vaccines, multi-/bi-specific antibodies, and the future of IO drug development.
Gain insights from industry leaders and innovators shaping the next generation of cancer immunotherapies.”
Other articles about Immunotherapy on OncoDaily.